EPO Patents = 3

Forward Citations = 7

Loading Chart...

5 inventors (with patents filed for the assignee):

Kevin N Sill (4 out of 48 patents)

Tomas Vojkovsky (4 out of 11 patents)

Adam Carie (4 out of 10 patents)

4. Suzanne Bakewell (2 out of 2 patents)

5. Jyothi Sethuraman (2 out of 2 patents)

6. Hooshmand Sheshbaradaran (6 patents)

6 patents: Sort by Forward Citations

1. 12415825 - Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereof (2025-09-16),

2. 11739111 - Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereof (2023-08-29),

3. 11633380 - Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer (2023-04-25),

4. 11040993 - Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereof (2021-06-22),

5. 10821095 - Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer (2020-11-03),

6. 10611787 - Manufacture of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereof (2020-04-07),

Bold Therapeutics is a biopharmaceutical company focused on developing innovative cancer therapies. Our lead product candidate, BOLD-100, is a first-in-class anti-resistance compound that has shown promising results in preclinical studies. With a dedicated team of scientists and researchers, we are committed to advancing therapeutics that address unmet medical needs in oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

6 Patents

#144 in Vancouver

#2,339 in Canada

Vancouver, Canada

Bold Therapeutics, Inc.